References
- Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proc 2003;78:21–33.
- Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996;334:488–493.
- Coleman RE. Bisphosphonates: clinical experience. Oncologist 2004;4:14–27.
- Coleman R. The use of bisphosphonates in cancer treatment. Ann NY Acad Sci 2011;1218:3–14.
- Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809–1822.
- Terpos E, Dimopoulos MA, Sezer O, et al. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia 2010;24:1700–1712.
- Lund T, Abildgaard N, Delaisse JM, et al. Effect of withdrawal of zoledronic acid treatment on bone remodelling markers in multiple myeloma. Br J Haematol 2010;151:92–93.
- Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377–387.